Ability to Monitor National Responses to the HIV Epidemic
                "Beyond Viral Suppression": Findings From Six European
                Countries. by Safreed-Harmon, Kelly et al.
ORIGINAL RESEARCH
published: 20 March 2020
doi: 10.3389/fpubh.2020.00036
Frontiers in Public Health | www.frontiersin.org 1 March 2020 | Volume 8 | Article 36
Edited by:
Amelia Kekeletso Ranotsi,
Maluti Adventist College, Lesotho
Reviewed by:
Moira Jean McKinnon,
Western Australia Country Health
Service (WACHS), Australia
Marisa Theresa Gilles,
Western Australian Center for Rural
Health (WACRH), Australia
*Correspondence:
Jeffrey V. Lazarus
jeffrey.lazarus@isglobal.org
Specialty section:
This article was submitted to
Public Health Policy,
a section of the journal
Frontiers in Public Health
Received: 21 November 2019
Accepted: 05 February 2020
Published: 20 March 2020
Citation:
Safreed-Harmon K, Kall M,
Anderson J, Azzopardi-Muscat N,
Behrens GMN, d’Arminio Monforte A,
Davidovich U, Noori T and Lazarus JV
(2020) Ability to Monitor National
Responses to the HIV Epidemic
“Beyond Viral Suppression”: Findings
From Six European Countries.
Front. Public Health 8:36.
doi: 10.3389/fpubh.2020.00036
Ability to Monitor National
Responses to the HIV Epidemic
“Beyond Viral Suppression”: Findings
From Six European Countries
Kelly Safreed-Harmon 1, Meaghan Kall 2, Jane Anderson 3, Natasha Azzopardi-Muscat 4,
Georg M. N. Behrens 5, Antonella d’Arminio Monforte 6, Udi Davidovich 7,8, Teymur Noori 9
and Jeffrey V. Lazarus 1* on behalf of the HIV Outcomes Beyond Viral Suppression
Study Group
1 Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain, 2 Public Health
England, National Infection Service, London, United Kingdom, 3Homerton University Hospital NHS Foundation Trust,
Jonathan Mann Clinic, London, United Kingdom, 4Department of Health Services Management, Faculty of Health Sciences,
University of Malta, Msida, Malta, 5Department for Clinical Immunology and Rheumatology, Hannover Medical School,
Hanover, Germany, 6 Institute of Infectious and Tropical Diseases, Department of Health Sciences, ASST Santi Paolo e
VCarlo, University of Milan, Milan, Italy, 7Department of Infectious Diseases, Research and Prevention, Public Health Service
of Amsterdam, Amsterdam, Netherlands, 8Department of Infectious Diseases, Amsterdam Infection and Immunity Institute
(AIII), Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, 9 European Centre for Disease Prevention and
Control, Solna, Sweden
Objective: With more people living with HIV (PLHIV) ageing into their 50s and beyond
in settings where antiretroviral therapy is widely available, non-AIDS comorbidities and
health-related quality of life (HRQoL) are becoming major challenges. Information is
needed about whether national HIV monitoring programmes have evolved to reflect the
changing focus of HIV care.
Methods: We created a 56-item English-language survey to assess whether health
systems report on common health-related issues for people with HIV including physical
and mental health comorbidities, HRQoL, psychosocial needs, and fertility desires. One
expert was identified via purposive sampling in each of six countries (Estonia, Italy, the
Netherlands, Slovenia, Sweden, and Turkey) and was asked to participate in the survey.
Results: Three respondents reported that the current monitoring systems in their
countries do not monitor any of four specified aspects of 10 comorbidities including bone
loss, cardiovascular disease, and neurocognitive disorders. Two respondents stated that
their countries potentially can report on leading causes of hospital admission among
PLHIV, and five on leading cases of death. In three countries, respondents reported that
there was the ability to report on the HRQoL of PLHIV. In two countries, respondents
provided data on the percentage of PLHIV denied health services because of HIV status
in the past 12 months.
Conclusions: This study identified areas for potential HIV monitoring improvements in
six European countries in relation to comorbidities, HRQoL, discrimination within health
systems, and other issues associated with the changing nature of the HIV epidemic.
Safreed-Harmon et al. Monitoring HIV Beyond Viral Suppression
It also indicated that some countries either currently monitor or have the ability to monitor
some of these issues. There are opportunities for health information systems in European
countries to expand the scope of their HIVmonitoring in order to support decision-making
about how the long-term health-related needs of PLHIV can best be met.
Keywords: comorbidity, Europe, health-related quality of life, HIV, indicator, monitoring
INTRODUCTION
Effective health policy-making and health system management
require up-to-date information about people’s health-related
needs and about health system performance in response to those
needs (1). Furthermore, the public reporting of such information
promotes accountability by enabling stakeholders to assess the
extent to which governments are meeting their health-related
obligations (2). In the HIV field, many national governments
participate in regional and global monitoring initiatives that
require standardised reporting on selected indicators while also
collecting data on additional indicators for national monitoring
purposes. Decisions about which indicators to include in
monitoring can greatly shape national HIV responses since
evidence of the need for specific services and commodities can
be a major factor in determining how health system resources
are allocated.
The highly effective antiretroviral therapy (ART) regimens
introduced in the late 1990s have transformed HIV into a
manageable long-term condition in the sense that the life
expectancy of people who initiate ART at an early stage of
infection is close to that of the general population (3). However,
as more people living with HIV (PLHIV) age into their 50s and
beyond, additional threats to their health and well-being are
emerging (4, 5). For multiple reasons, including HIV-mediated
chronic inflammation as well as lifestyle factors, PLHIV have
higher levels of multimorbidity than the general population
(6–8). The disease burden associated with comorbidities is an
increasingly prominent concern in HIV clinical care in settings
where ART is widely available. A 2018 review found that
PLHIV are twice as likely as HIV-negative people to develop
cardiovascular disease, and that the global burden of HIV-
associated cardiovascular disease has increased three-fold from
1990 to 2015 (9). PLHIV likewise have a higher prevalence of
depression, which is underdiagnosed in this population (10).
Common causes of hospitalisation among PLHIV in Europe
include cardiovascular, respiratory, renal, liver, and psychiatric
conditions (11).
In 2014, UNAIDS called for international action on an
ambitious three-part target: by 2020, 90% of PLHIV were to
know their HIV status, 90% of those diagnosed were to be
receiving ART, and 90% of those receiving ART were to be
virally suppressed (12). The “90-90-90” target has spurred many
countries to concentrate resources on increasing diagnosis of
HIV and reducing the proportions of diagnosed individuals who
Abbreviations: ART, antiretroviral therapy; ECDC, European Centre for
Disease Prevention and Control; HRQoL, health-related quality of life; NCDs,
non-communicable diseases; PLHIV, people living with HIV; WHO, World
Health Organization.
do not initiate treatment and do not achieve viral suppression.
Meanwhile, there is a dearth of high-level policy guidance
addressing what else countries should strive to achieve with
regard to the growing number of PLHIV who are likely to live
for many years into the future. A “fourth 90” target addressing
the health-related quality of life (HRQoL) of PLHIV has been
proposed [Figure 1; (5, 13)], but no consensus has emerged
regarding how HRQoL should be defined in this context or how
progress toward such a target should be measured.
European countries are experiencing the changing HIV care
paradigm ahead of many other countries, and European health
systems have the opportunity to set an instructive example
by adapting their HIV services to reflect a model of care
that is suitable for long-term conditions. However, little is
known about whether national HIV monitoring programmes
in Europe have evolved in accordance with changing needs.
Without the right information, health systems will be limited
in their efforts to meet new HIV-related health challenges. This
study assesses the ability of health systems in six European
countries to report on indicators that can speak to the health
and psychosocial needs of people who are living with HIV on a
long-term basis.
METHODS
Study Instrument
We identified common health-related issues for people with
controlled HIV using an iterative process of desk research
and consultation with an expert panel. For the literature
review, we used PubMed to identify relevant English-language
publications, using the term “HIV” in combination with terms
such as “comorbidity,” “Europe,” “epidemiology,” and “health-
related quality of life.” We prioritised review articles and
large longitudinal cohort studies published after 2010 but did
not exclude other sources. We also examined relevant clinical
guidelines such as those published by the European AIDSClinical
Society as well as key gray literature sources that were located
through internet searches. The expert panel members who
advised on the selection of relevant health-related issues to be
addressed in the study included European researchers, clinicians,
epidemiologists, policymakers, industry representatives, and civil
society stakeholders including PLHIV.
We created a 56-item English-language survey to investigate
the readiness of national health systems to report on the
chosen health-related issues as part of their routine HIV
monitoring (Supplementary File). The survey was organised
into seven thematic sections: HIV clinical management,
comorbidities, health-related quality of life, psychosocial
services, discrimination within health systems, preconception
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FIGURE 1 | A proposed “fourth 90” target for health-related quality of life [source: Safreed-Harmon et al. (13)].
planning, and general issues. A number of survey items asked
about specific indicators in these areas, instructing respondents
to characterise national reporting on these issues by choosing
one of four possible responses: (a) national HIV monitoring
does include reporting on such an indicator; (b) national HIV
monitoring systems collect data that would allow for reporting
on such an indicator; (c) national HIV monitoring systems
could be easily modified to collect data that would allow for
reporting on such an indicator; or (d) national HIV monitoring
systems could not be easily modified to collect data that would
allow for reporting on such an indicator. In order to keep the
survey short enough for respondents to be willing to complete all
items, we largely restricted the content to questions such as these
about reporting capacity rather than about the actual data being
reported. However, some items requested data, e.g., respondents
were asked to report leading causes of hospital admission and
death among PLHIV and to report the percentage of PLHIV
denied health services because of their HIV status.
The survey underwent multiple rounds of revision in response
to input from co-authors regarding the topics addressed as well as
the structure of the survey questions. Four co-authors reviewed it
for clarity and ease of navigation before it was finalised.
Study Sample
The study group’s nine members, who include experts in
monitoring, policy, and health system responses to HIV
in Europe, were consulted regarding the selection of study
countries. The objective was to construct a geographically
diverse sample that also included countries with diverse
health systems and different levels of robustness in their
national HIV monitoring activities. Through this process,
Estonia, Italy, the Netherlands, Slovenia, Sweden, and
Turkey were selected as study countries. We then identified
one expert to serve as the respondent in each country
via purposive sampling, drawing on multiple co-authors’
networks of contacts in the countries of interest to select
this person. The objective was to choose the respondents
with the most comprehensive knowledge of their countries’
national HIV monitoring mechanisms and resources.
There were no other eligibility criteria, and the experts
identified included both individuals working directly for
government agencies as well as individuals working closely
with those agencies. These experts were encouraged to
collaborate with other experts in their country to present a
comprehensive response.
Data Collection and Analysis
The survey was administered from 20 April to 30 June 2018 using
a Microsoft Word survey document. After data-cleaning, we
compiled findings in Microsoft Excel and performed descriptive
analyses. For reporting purposes, findings were organised into
two domains: (1) ability to report on indicators of interest; and
(2) data for selected indicators. In the first domain, a country
was considered to be able to report on a specified indicator if
the respondent reported that either: (a) national HIVmonitoring
does include reporting on such an indicator; (b) national HIV
monitoring systems collect data that would allow for reporting
on such an indicator; or (c) national HIV monitoring systems
could be easily modified to collect data that would allow for
reporting on such an indicator. We classified a country as not
able to report if the respondent reported that national HIV
monitoring systems were not currently able and could not be
easily modified to collect data that would allow for reporting
on such an indicator. Findings relating to comorbidities, health-
related quality of life, psychosocial services, discrimination
within health systems, and fertility desires are presented in terms
of the two domains previously named: reporting ability and data
for selected indicators.
RESULTS
Participating Study Countries
All six national monitoring experts who were approached about
the survey completed it for a 100% response rate. Table 1
describes the HIV epidemiology of the countries included.
Reporting Ability
Regarding ability to report on comorbidities, respondents in
three countries (Estonia, Italy, and Turkey) reported that
the countries could not monitor any of the four specified
aspects (testing/screening offer, uptake, diagnosis, or treatment)
of 12 of the 17 comorbidities (Table 2). The comorbidities
reported to be most comprehensively monitored by study
countries were drug dependence, hepatitis B virus, hepatitis
C virus, and tuberculosis. The comorbidities reported to
be least comprehensively monitored were anxiety, chronic
pain syndrome and depression, all of which could only
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TABLE 1 | HIV epidemiology in study countries.
Estonia Italy The Netherlands Slovenia Sweden Turkey
European areaa East West West Centre West Centre
Estimated number of people living with HIV 11,000b 127,000b 22,900b 970c 7,700b Unknown
Antiretroviral therapy coverage among people diagnosed with HIVb 40% 88% 88% 91% 95% Unknown
New HIV diagnoses in 2016a 229 3,451 745 58 429 2,438
aEuropean Centre for Disease Prevention and Control/WHO Regional Office for Europe (14).
bEuropean Centre for Disease Prevention and Control (15).
cUNAIDS (16).
TABLE 2 | Reported ability of six* European countries to report on indicators for comorbidity screening/testing, diagnosis and treatment in PLHIV.
Indicators addressing
whether PLHIV are offered
screening/testing for
specified comorbidities
Indicators addressing
whether PLHIV are
screened/tested for
specified comorbidities
Indicators addressing
whether PLHIV are
diagnosed with specified
comorbidities
Indicators addressing
whether PLHIV are treated
for specified comorbidities
Alcohol dependence SVN SWE SVN SWE NLD SVN SWE SVN SWE
Anxiety SVN SWE SVN SWE SVN SWE SVN SWE
Bone loss NLD SVN SWE NLD SVN SWE NLD SVN SWE NLD SVN SWE
Cardiovascular disease NLD SVN SWE NLD SVN SWE NLD SVN SWE NLD SVN SWE
Chronic pain syndrome SVN SWE SVN SWE SVN SWE SVN SWE
Depression SVN SWE SVN SWE SVN SWE SVN SWE
Drug dependence EST SVN SWE EST SVN SWE EST ITA NLD EST SVN SWE
SVN SWE
Hepatitis B virus EST SVN SWE EST NLD SVN EST NLD SVN NLD SVN SWE
NLD SWE SWE
Hepatitis C virus EST NLD SVN EST NLD SVN EST NLD SVN NLD SVN SWE
SWE SWE SWE
Liver disease other than
chronic viral hepatitis
SVN SWE NLD SVN SWE NLD SVN SWE SVN SWE
Neurocognitive disorders SVN SWE NLD SVN SWE NLD SVN SWE SVN SWE
Non-AIDS malignancies NLD SVN SWE NLD SVN SWE NLD SVN SWE NLD SVN SWE
Renal disease NLD SVN SWE NLD SVN SWE NLD SVN SWE NLD SVN SWE
Respiratory disease SVN SWE NLD SVN SWE NLD SVN SWE SVN SWE
Sexual dysfunction SVN SWE NLD SVN SWE NLD SVN SWE NLD SVN SWE
Sexually transmitted infections EST SVN SWE NLD SVN SWE NLD SVN SWE SVN SWE
Tuberculosis EST NLD SVN EST ITA NLD EST ITA NLD EST ITA NLD
SWE SVN SWE SVN SWE SVN SWE
EST, Estonia; ITA, Italy; NLD, The Netherlands; SVN, Slovenia; SWE, Sweden.
*Turkey was not able to monitor any aspect of any of the comorbidities listed.
be monitored by Slovenia and Sweden. There were no
comorbidities that all six countries were reported to be able
to monitor.
According to respondents, two countries had the ability to
report on leading causes of hospital admission among PLHIV,
while five had the ability to report on leading causes of death
(Table 3). Respondents indicated that three countries had the
ability to report on the health-related quality of life of PLHIV.
Two countries were reported to be able to make modifications to
report on the percentage of PLHIV who want to have children,
and one, to be able to make modifications to report on the
percentage of PLHIV who have an unmet need for preconception
planning services.
Respondents were asked to list up to three indicators
used at the national level for monitoring psychosocial service
provision (e.g., housing, employment, social support), but none
of the respondents reported any psychosocial indicators. Three
respondents indicated in comments that no such indicators
were used at the national level in their countries. The
respondent from Sweden noted that while there was not
regular data collection for psychosocial indicators, the Public
Health Agency of Sweden had conducted a survey on this
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TABLE 3 | Reported ability of six European countries to report on causes of hospital admission, causes of death, health-related quality of life, and fertility desires in PLHIV
(N = 6 countries).
Currently reported Data available Could be modified Could not be modified
Leading causes of hospital admission
among PLHIV
NLD SWE EST ITA SVN
TUR
Leading causes of death among PLHIV NLD SVN EST ITA SWE TUR
Health-related quality of life among PLHIV SWE NLD SVN EST ITA TUR
Percentage of PLHIV who want to have
children
SVN SWE EST ITA NLD
TUR
Percentage of PLHIV who have an unmet
need for preconception planning services
SVN EST ITA NLD
TUR SWE
Currently reported = National HIV monitoring includes reporting on such an indicator.
Data available = National HIV monitoring systems collect data that would allow for reporting on such an indicator.
Could be modified = National HIV monitoring systems could be easily modified to collect data that would allow for reporting on such an indicator.
Could not be modified = National HIV monitoring systems could not be easily modified to collect data that would allow for reporting on such an indicator.
EST, Estonia; ITA, Italy; NLD, The Netherlands; SVN, Slovenia; SWE, Sweden; TUR, Turkey.
issue and planned to repeat the survey approximately every
five years.
Indicator Data
Respondent reporting on the five leading causes of hospital
admission and five leading causes of death among PLHIV are
shown in Table 4. Respondents in five countries could not report
on leading causes of hospital admission, and information for the
sixth country, Sweden, reflected the respondent’s estimates. In
comments from two countries, respondents indicated that data
for reporting on this indicator existed: Italy was said to have a
national hospital admissions database from which HIV records
could be extracted, and the Netherlands was said to have uncoded
free text collected in HIV surveillance reports. Respondents in a
larger number of countries were able to report data on leading
causes of death.
Respondents in two countries provided data on the percentage
of PLHIV who had been denied health services because of
their HIV status in the past 12 months; respondents from the
remaining four countries were unable to do so (Table 5).
DISCUSSION
This study in six European countries assessed aspects of health
system monitoring that are considered relevant to the care of
PLHIV on a long-term basis. Based on input from respondents
who are regarded as top HIV monitoring experts in their
countries, it found that a number of countries cannot report on
indicators for many major comorbidities in PLHIV populations,
including highly prevalent comorbidities such as cardiovascular
disease and depression. It also identified large monitoring gaps
in relation to health-related quality of life, fertility desires,
psychosocial services, and discrimination within health systems.
There are multiple processes for monitoring progress against
HIV in Europe, with most countries reporting to UNAIDS,
the World Health Organization (WHO) and the European
Centre for Disease Prevention and Control (ECDC) in addition
to conducting further national-level monitoring to inform
in-country decision-making. UNAIDS and ECDC reporting
influence country-level monitoring activities in Europe, while
at the same time, decisions about which indicators to include
in multi-country monitoring activities are influenced by what
is known about countries’ reporting ability. The reported lack
of ability of study countries to monitor some issues addressed
in our survey suggests a need for country-level stakeholders
to re-assess their HIV monitoring priorities as well as a need
for regional stakeholders to provide technical support in this
area. The reported lack of ability to monitor many comorbidities
is particularly disquieting in light of modelling research that
indicates that the large comorbidity burden among PLHIV will
continue to increase in the coming years (18).
In the interest of capturing as much information as
possible, we sought to learn about the monitoring of each
comorbidity included in our study in four domains spanning the
diagnosis and treatment spectrum: whether PLHIV are offered
screening/testing, whether they are screened/tested, whether
they are diagnosed and whether they are treated. Three or
more countries had the ability to report on all four domains
for some comorbidities. While this is a welcome finding, the
methodological decision to ask survey respondents to report in
terms of the four domains is not meant to imply that health
systems should be asked to monitor all four of them. Where
health systems do not currently have robust reporting processes
in place, a better use of resources would be to focus on collecting
data at one stage of the diagnostic process for each comorbidity
of interest, e.g., whether PLHIV are screened for cardiovascular
disease and whether PLHIV who have been diagnosed with drug
dependence receive treatment.
The health-related quality of life of PLHIV has long been
a matter of interest for researchers (19), practitioners and
community stakeholders, but there is little published information
about how this issue has been monitored by health systems.
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TABLE 4 | Leading causes of hospital admission and death among PLHIV in six European countries as reported by respondentsa.
Estonia Italy The Netherlands Slovenia Sweden Turkey
Hospital admissionsb
1 – – – – 80% late HIV diagnosis –
2 – – – – 15% ageing-related
comorbidities
–
3 – – – – 5% issues related to drug
addiction
–
4 – – – – – –
5 – – – – – –
Year data
collected
2017
Deathsc
1 – 24% chronic viral
hepatitis
25% non-AIDS
malignancies
There are only 1 to 5 deaths per year:
they are in very late presenters:
opportunistic infections, lymphomas
and also suicidesd
Very few deaths. I believe it
was 10 during 2017. No
specific patternd
–
2 – 11% non-Hodgkin
lymphoma
15% cardiovascular disease –
3 – 12% septicemia 11% AIDS –
4 – 16% pneumonia 8% non-AIDS infections –
5 – 10% heart disease 8% lung disease –
Year data
collected
2006–2010 2016c
aSince respondents were asked to report the proportions of hospital admissions and deaths attributable to the top five causes as percentages of total hospital admissions and deaths,
percentages may not sum to 100%.
bReporting for Sweden reflects estimates.
cFor The Netherlands, reporting was incomplete at the time the survey was submitted and cause of death was unknown for 12% of deaths.
dVerbatim transcription from survey response.
“–” indicates that no data were reported.
Furthermore, we are not aware of any expert guidance on the
use of HRQoL indicators in national HIV monitoring. In 2018,
the Dublin Declaration questionnaire (20) included an item
about HRQoL for the first time, asking respondent countries
to report on whether or not they included HRQoL in their
HIV monitoring. Only five of 48 responding countries answered
that they did so (personal communication, European Centre for
Disease Prevention and Control to Jeffrey V. Lazarus, 5 June
2018). In light of this finding, it is notable that one of the six
countries in our study currently carries out reporting on the
HRQoL of PLHIV and two more countries said they were able
to easily modify their current monitoring systems to carry out
such reporting. It may be that there is widespread readiness
to incorporate HRQoL into HIV monitoring in the European
region, and this is perhaps an opportune time for stakeholders
to identify best practices for health information systems to adopt
in this regard.
On the other hand, there was little evident capacity to monitor
HIV-related discrimination within health systems, which is cause
for concern in light of the persistence of such discrimination
(21–24) and the impact that it has on the health and well-
being of PLHIV (25–27). In 2017, UNAIDS introduced a new
indicator for countries to report on in 2018: “Percentage of
people living with HIV who report experiences of HIV-related
discrimination in health-care settings” (28). This indicator was
drawn from an item in the widely used People Living with
HIV Stigma Index, a survey developed by a coalition of civil
society organisations in collaboration with UNAIDS (29). Our
results point to a significant monitoring gap, and in light of
TABLE 5 | Discrimination against PLHIV within health systems in six European
countries.
Of all PLHIV, what percentage report being denied health services (including
dental care) because of HIV status in past 12 months?a
Estonia Italy The Netherlands Slovenia Sweden Turkey
– – – 10%b – 20%c
aAdapted from an indicator in the People Living with HIV Stigma Index (GNP+, ICW,
UNAIDS); http://www.stigmaindex.org.
bSource of data unknown.
cRespondent indicated that data were collected in 2011 and were published in Gökengin
et al. (17).
“–” indicates that no data were reported.
the link between HIV-related stigma and poor health outcomes
(30), stakeholders are advised to consider whether the Stigma
Index indicator selected by UNAIDS should also be added to
European regional reporting, which would further encourage
national health systems to take up the indicator and collect robust
monitoring data.
Given the high level of collaboration and coordination among
many European countries in the response to HIV, the use of
standardized “fourth 90” HIV care indicators across multiple
countries would be beneficial to researchers, policy-makers, and
other stakeholders. The optimal way for European countries
to choose such indicators would be through a coordinated
process that yields recommendations for a small number of
new indicators to be used by national governments. In seeking
consensus on indicators, stakeholders should consider how
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to minimise the reporting burden for countries and align
data collection with current country-level monitoring activities,
particularly in regard to comorbidity monitoring options. With
such a large number of comorbidities contributing to the disease
burden in PLHIV, the objective should not be to capture
information about numerous comorbidities but rather to choose
some comorbidities and other indicators as proxies for how
health systems are managing comorbidity care in PLHIV overall.
Such a process should take into account the possible need to
harmonise definitions of some comorbidities such as alcohol
dependence and sexual dysfunction.
Efforts to strengthen this aspect of the HIV response might
benefit from consideration of lessons emerging from the evolving
response to non-communicable diseases (NCDs) since in some
regards the HIV and NCD epidemics are challenging health
systems in similar ways (31). In a landmark 2018 report on
health system responses to NCDs, action points identified by the
WHO Regional Office for Europe encompassed issues such as
multidisciplinary primary care, people-centred care, and service
integration and coordination (32). In the coming years, strategies
for monitoring progress on issues such as these are likely to
become increasingly relevant to stakeholders in the HIV field.
This study has multiple limitations. The collection of data
from only six of the 53 countries in the WHO European Region
limits the representativeness of study findings, and a larger
number of countries would need to be surveyed to acquire an
evidence base for making recommendations about indicators
that should be incorporated into national HIV monitoring
throughout the region. The recruitment of survey respondents
who are regarded as top HIV monitoring experts in their
countries may have resulted in selection bias if this strategy led
to a lack of representation of countries with HIV monitoring
systems that are not sufficiently advanced for any one individual
to be regarded as an expert in this area. In study countries
where more than one person might be considered suitably
knowledgeable about the issues of interest, our choice of experts
might be biased by unknown variables. Since only one expert was
asked to respond to the survey in each study country, findings
directly reflect any gaps in the knowledge of these individuals
regarding HIV monitoring in their countries.
The accuracy of the information reported by the survey
respondents was not confirmed by other sources, and it may
reflect errors or biases on the part of respondents. Biases among
respondents also may have influenced some of the estimates and
explanations provided in response to survey items that requested
data. Country data for leading causes of hospitalisation and death
among PLHIV and for discrimination within health systems were
not collected using standardised methodologies and definitions.
Hence, it is not possible to make meaningful cross-country
comparisons. The survey item that asked for the percentage of
PLHIV who report being denied health services did not elaborate
criteria for what constitutes denial of health services, and thus the
outcome measure could have been interpreted in multiple ways.
CONCLUSIONS
Findings from our study indicate that although the existing
gaps may be considerable, there are opportunities for health
information systems in European countries to expand the scope
of their HIV monitoring in order to support decision-making
about how the long-term health-related needs of PLHIV can best
be met. Scaling up this survey to involve a larger number of
European countries would provide stronger evidence regarding
how to build on monitoring activities and resources that are
already in place. Studies of HIV monitoring capacity are also
needed in other regions, including Africa and Asia, where low-
and middle-income countries with widespread access to HIV
treatment are beginning to face HIV care challenges that similarly
call for integrated and people-centred health system responses
(31, 33). The larger goals of reorienting monitoring systems to
better address the chronic care dimensions of HIV should be to
transform HIV care into a more holistic undertaking and to help
guide the integration of health system responses to HIV and to
other chronic diseases.
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